Primary Breast Cancer Clinical Trial
Official title:
Using Technology to Enhance Cancer Communication and Improve Clinical Outcome: Effectiveness of the CHESS Ehealth Cancer Support Intervention in Population-Based Care Study
Verified date | February 2016 |
Source | University of Wisconsin, Madison |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study's aim is to provide information about the clinical and business cases for
comprehensive interactive cancer communication systems (ICCS) in the context of real world
use for cancer care.
This study will be conducted within the Kaiser Permanente Northwest (KPNW) healthcare system.
Outcomes for this study include amount of ICCS use and women's ratings of cancer information
competence, perceived social support, and emotional well being. Secondary outcomes will
include healthcare utilization, cost-effectiveness, and clinician ratings of healthcare
visits.
Status | Completed |
Enrollment | 368 |
Est. completion date | August 2013 |
Est. primary completion date | August 2013 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - All subjects must be within 2 months of their primary breast cancer diagnosis, - All subjects must be at least 18 years of age Exclusion Criteria: - Illiterate - Homeless |
Country | Name | City | State |
---|---|---|---|
United States | Kaiser Permanente Northwest | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Amount of ICCS use and women's ratings of cancer information competence, perceived social support, and emotional well being. Secondary outcomes will include healthcare utilization, cost-effectiveness, and clinician ratings of healthcare visits. | 12 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05923177 -
Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3
|
Phase 1 | |
Recruiting |
NCT03270007 -
Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
|
Phase 4 | |
Completed |
NCT00527449 -
Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel
|
Phase 2 | |
Completed |
NCT04468113 -
Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy
|
||
Recruiting |
NCT03711877 -
Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study)
|
Phase 3 | |
Active, not recruiting |
NCT01019616 -
Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy
|
Phase 3 | |
Completed |
NCT01314833 -
Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
|
Phase 3 | |
Completed |
NCT04127019 -
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
|
Phase 3 | |
Terminated |
NCT00172068 -
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
|
Phase 2 | |
Completed |
NCT01049425 -
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
|
Phase 3 | |
Recruiting |
NCT01840293 -
Breast Cancer Proteomics and Molecular Heterogeneity
|
||
Completed |
NCT01779479 -
Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)
|
Phase 2 | |
Completed |
NCT04277338 -
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3
|
Phase 1 | |
Recruiting |
NCT05445050 -
mULM to Support Breast Cancer Diagnosis and Therapy
|
N/A | |
Completed |
NCT00793377 -
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
|
Phase 3 |